市場調查報告書
商品編碼
1297823
全球腎臟功能測試市場 - 2023-2030年Global Kidney Function Tests Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
全球腎功能測試市場在2022年達到了9億美元,預計到2030年將見證有利可圖的成長,達到14億美元。在2023-2030年的預測期內,該市場預計將呈現6.3%的複合成長率。
腎功能測試可以識別腎臟或腎功能紊亂,並協助醫生開出適當的藥物。稀釋試驗、清除試驗和其他類型的腎功能測試都可以使用。腎臟疾病,如因體液過多導致的排尿困難、手或腳水腫、臉部腫脹等,都可以通過腎功能測試來確定。
推動市場成長的因素包括美國食品和藥物管理局的批准和主要參與者推出的腎功能測試的新產品。例如,2022年7月12日,將智慧手機鏡頭整合到醫療設備中的全球先驅Healthy.io宣布,Minuteful腎臟測試已獲得美國食品和藥物管理局(FDA)的510(k)許可,可用於家庭使用。
全球慢性腎臟病發病率和流行率的上升是推動全球腎功能檢測市場成長的主要因素。例如,根據2021年NIDDK的數據,在美國,每七個成年人中就有一個以上患有慢性腎臟病(CKD),估計總共有3700萬人。
患有糖尿病或高血壓的美國人患CKD的風險甚至更高,這是腎臟疾病的兩個最常見原因。腎臟疾病影響了近三分之一的糖尿病患者和五分之一的高血壓患者。
此外,根據美國疾病控制和預防中心(CDC)的《2021年美國慢性腎臟病》,CKD在女性(14%)中的發病率略高於男性(12%),在非西班牙裔黑人成年人中(16%)比非西班牙裔白人成年人(13%)或非西班牙裔亞洲人(13%)更常見。因此,CKD的頻率將推動市場擴張。
腎功能測試的高成本,以及新興國家和發展中國家的低接受率,將扼殺市場擴張。由於修改公式,臨床診斷為腎臟疾病的人數增加,意味著更多的人可能會收到調整劑量的建議,或對某些可能干擾腎臟功能或腎臟過濾不良的藥物的禁忌症。
COVID-19的大流行對醫療系統和市場產生了適度的影響。根據2020年4月發表在medRXiv上的一項研究,在患有各種傳染病和有害疾病的人中經常觀察到COVID-19尿失禁。已發現0至12歲的兒童有小光型COVID-19的尿路COVID-19暴露。
COVID-19尿路感染是在疾病發生後的第一至第五天之間發現的。腎功能標誌物用於確定腎臟的功能如何。有些訊號是放射性的,也有非放射性的。它們顯示了腎臟的腎小球濾過率以及濃縮和稀釋能力(腎小管功能)。許多人寧願在商店購買腎功能測試,也不願在網上購買。
俄羅斯-烏克蘭估計對全球腎功能檢測市場的影響很小,因為這個地區的流行率很低,而且沒有關鍵的市場參與者。然而,原料、測試產品和設備的進出口的影響,預計在預測期內對全球腎功能測試市場的影響不大。
人工智慧預計將對全球子癇前期市場產生積極的影響。由人工智慧驅動的決策支持系統可以幫助醫護人員對腎臟診斷和治療方案做出明智的判斷。這些系統能夠分析病人數據,將其與當前的醫學知識進行比較,並根據循證指南提出建議。這有助於醫生為特定患者選擇最佳的診斷測試、藥物或行動。
The Global Kidney Function Tests Market reached US$ 0.9 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 1.4 billion by 2030. The market is expected to exhibit a CAGR of 6.3% during the forecast period 2023-2030.
Kidney function tests identify kidney or renal function disorders and assist doctors in prescribing appropriate medicine. Dilution tests, clearance tests and other types of kidney function tests are available. Kidney diseases such as trouble urinating due to excess bodily fluids, edema in the hands or feet, and swollen face can be identified using a kidney function test.
The factors driving the growth of the market include FDA approvals and the launch of new products by the key players for kidney function tests. For instance, on July 12, 2022, Healthy.io, the global pioneer in integrating the smartphone camera into a medical device, announced that the Minuteful Kidney test has acquired 510(k) clearance from the US Food and Drug Administration (FDA) for home use.
The global rise in the incidence and prevalence of chronic kidney disease is a major factor driving the growth of the global kidney function testing market. For instance, according to NIDDK 2021, Chronic kidney disease (CKD) affects more than one in every seven adults in the United States, totaling an estimated 37 million people.
The risk of CKD is even higher for Americans who have diabetes or high blood pressure, the two most frequent causes of kidney disease. Kidney disease affects nearly one-third of people with diabetes and one-fifth of people with high blood pressure.
Additionally, according to the Centers for Disease Control and Prevention's (CDC) Chronic Kidney Disease in the United States, 2021, CKD is slightly more prevalent in women (14%) than in men (12%), and it is more common in non-Hispanic Black adults (16%) than in non-Hispanic white adults (13%) or non-Hispanic Asian people (13%). Thus, the frequency of CKD will fuel market expansion.
The high cost of kidney function tests, as well as the low acceptance rate in emerging and developing nations, will stifle market expansion. The increased number of people with a clinical diagnosis of kidney disease as a result of the modified formula means that more people may receive recommendations for dose adjustments or contraindications for certain drugs that may interfere with kidney function or be poorly filtered by the kidneys.
The pandemic of COVID-19 has had a moderate impact on healthcare systems and the market. According to a study published in medRXiv in April 2020, COVID-19 urine incontinence was often observed in persons with a variety of infectious and harmful illnesses. Children aged 0 to 12 who have a little light type of COVID-19 have been found to have urinary tract COVID-19 exposure.
COVID-19 urinary tract infections were identified between the first and fifth days after the disease's onset. Kidney function markers are used to determine how well the kidneys function. Some signals are radioactive as well as non-radioactive. They demonstrate the kidneys' glomerular filtration rate as well as their concentrating and diluting capacities (tubular function). Many people would rather buy a kidney function test at a store than online.
The Russia-Ukraine is estimated to have a minimal impact on the global kidney function tests market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test products and devices is anticipated to have little influence over the global kidney function tests market in the forecast period.
Artificial intelligence is anticipated to impact the global preeclampsia market positively. Artificial intelligence-powered decision support systems can help healthcare personnel make well-informed judgements about renal diagnosis and treatment options. These systems are capable of analyzing patient data, comparing it to current medical knowledge and making suggestions based on evidence-based guidelines. This assists doctors in selecting the best diagnostic tests, drugs or actions for particular patients.
The global kidney function tests market is segmented based on product type, test type end user and region.
The Dipstick product type holds about 47.3% of the total kidney function tests market in the forecast period. Dipstick tests provide rapid results, usually within a few minutes, allowing for immediate assessment of kidney health. They are easy to use and do not require extensive laboratory equipment or specialized training, making them accessible in various healthcare settings, including clinics, emergency rooms and home.
This aids in the diagnosis of a variety of renal and urinary issues, including chronic kidney disease, bladder infections and kidney stones. Furthermore, the increasing number of people and important companies' strategies in renal function testing promote some growth.
For instance, Sweden's Elypta AB raised USD 7.0 million in January 2020 for a urine cancer screening test. Therefore, a patient's urine can reveal a lot of information about their health, increasing the use of dipsticks. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.
The North American region holds the second-largest share of the global kidney function tests market accounting for approximately 39.4% in the forecast period. Due to well-established healthcare infrastructure, widespread awareness of CKD and favorable reimbursement policies and government initiatives. Furthermore, the region's main manufacturers are focused on inventing innovative products.
For instance, Abbott HealthTab signed a non-assignable, pilot supplier distribution agreement with Abbott in November 2021 for i-STAT Alinity, a handheld blood chemistry analyzer. The partnership allows HealthTab to sell Abbott's POC i-STAT Alinity and associated creatinine tests in Canadian pharmacies, providing patients with important information regarding their kidney functioning.
The major global players in the market include: F. Hoffmann-La Roche Ltd, Nova Biomedical, Quest Diagnostics, 77 Elektronika Kft, ACON Laboratories, Inc., Beckman Coulter, Abbott, bioMerieux SA, OPTI Medical, Siemens Healthineers. among others.
The Global Kidney Function Tests Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 pages.
LIST NOT EXHAUSTIVE